Who We Are
Elevation Diagnostics is a high-complexity molecular testing laboratory dedicated to increasing Covid-19 testing capacity for the state of Colorado. We are the first CLIA/CAP lab in Colorado to offer the gold standard saliva PCR-test. Our tests are self-administered and we guarantee 24-hour turnaround time from when the sample arrives at the lab. We offer a seamless process from collection to result that makes the process easy and efficient. Our integrated process is designed to improve and elevate the testing experience from start to finish.
We bring industry expertise to every experimental challenge. Made up of a team of experienced scientists who have trained at the NIH, NYU and Bio-design Institute in the areas of infectious disease, molecular genetics and diagnostics, we solve some of the most difficult research problems and work with our customers to gain reproducible results.
We commit to the scientific process and believe that no experiment is too big or too challenging to execute. We harness the power of science through experimentation to produce impactful results.
Vice President, Business Operations
Robert is the Vice President of Operations for Elevation Diagnostics. Robert brings over 20 years of project and operations experience, including leading start-ups from inception through corporate acquisition and integration, to overseeing training and field data collection efforts for the Institute for Behavior Genetics and other national research studies. Robert is passionate about inspiring teams to perform at their best. From the startup phase to operational maturity, he thrives on bringing talented people together to collaborate, grow, and succeed.
Director of Laboratory Compliance and Qualitative Testing
Kristen joined Elevation Diagnostics and performs as the Company’s Director of Laboratory Compliance and Qualitative Testing. Kristen has extensive experience working within laboratory operations and profound knowledge of diagnostics assays. Kristen worked for National Jewish Health, an international recognized medical institution for over 9 years. At National Jewish, Kristen worked as a clinical laboratory supervisor and clinical scientist lead.
Peter Bryant-Greenwood, MD, MBA, FACHE, FCAP
Peter provides strategic and clinical leadership to our staff and works to identify and advise on best practice use cases in health informatics trends. Additionally, he works with our partner companies, and their affiliates, to create medical program strategy and offer advice on how to address evolving needs specific to virus response, respiratory disease, immunology, and environmental health. He holds multiple board certifications and fellowships, he has decades of clinical and biomedical research and development experience in multiple settings, including academia, biotechnology, startups, and clinical practice. Peter’s experiences in biomarker discovery, clinical genomics, proteomics, and clinical assay development are key factors for growing partnerships with top pharmaceutical companies and other industries to deliver long-term solutions for improving patient health. He most recently served as the Medical Director, Director of Molecular Genomics for the National Jewish Health Advanced Diagnostic Laboratories, as well as the Medical Director of the National Jewish Health Center for Genes, Environment and Health. National Jewish Health Center, located in Denver, CO, has been ranked the number one respiratory hospital in the World.
Kevin P. Rosenblatt, MD, PhD
Kevin has created, led and operated multiple companies across various types of fields. He assists Elevation and steers our long-term direction through initiatives and leveraging driving forces in the industry. In 2015, he served as the Director of a CLIA-certified clinical lab focused on protein assays using mass spectrometry (vitamin D, metabolites, toxicology, and therapeutic drug monitoring), genetic and genomic assays for cancer (companion diagnostics), and pharmaco-genomics testing (ADME-related genes) for oncology and numerous non-oncology diseases. In 2016, he worked in collaboration with the University of Houston’s College of Pharmacy signing out on molecularly diagnostics for hematopathology. He also served as the Chief Medical Officer (CMO) and Chief Scientific Officer (CSO) for the company, providing direction in future initiatives in the medical fields, technology development, and company vision.